ciglitazone has been researched along with Transfusion Reaction in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Transfusion Reaction: Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with ciglitazone, which inhibits platelet CD40L expression, had no effect on pulmonary and systemic inflammation compared to controls." | 3.77 | Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. ( Boon, L; Gerards, MC; Jongsma, G; Juffermans, NP; Tuinman, PR; Vlaar, AP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuinman, PR | 1 |
| Gerards, MC | 1 |
| Jongsma, G | 1 |
| Vlaar, AP | 1 |
| Boon, L | 1 |
| Juffermans, NP | 1 |
1 other study available for ciglitazone and Transfusion Reaction
| Article | Year |
|---|---|
Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury.
Topics: Acute Lung Injury; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Blood Platelets; Bronch | 2011 |